News
Can a new CEO fix Novo Nordisk's problems? This analyst says no.
Novo Nordisk (NVO) stock fell after announcing that CEO Lars Fruergaard Jørgensen will step down. BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination with Josh Lipton and Bullseye American Ingenuity Fund portfolio manager Adam Johnson to discuss the surprise C-suite change.
Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...
3don MSN
FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...
Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...
Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...
U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...
Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback